Interpace Biosciences to Host 3rd Quarter 2020 Economical Final results Meeting Contact on Thursday, …

PARSIPPANY, NJ, Jan. 20, 2021 (World NEWSWIRE) — Interpace Biosciences, Inc. (NASDAQ: IDXG) declared these…

PARSIPPANY, NJ, Jan. 20, 2021 (World NEWSWIRE) — Interpace Biosciences, Inc. (NASDAQ: IDXG) declared these days that it will hold its 3rd quarter 2020 economic benefits conference call and webcast after the shut of industry on Thursday, January 21, 2021 at 4:30 p.m. ET.

        Purpose: To update the current market on Interpace’s third quarter 2020 fiscal results
        Date and Time: Thursday, January 21, 2021 at 4:30 p.m. ET
        Dial-in Quantity (Domestic): +1 (877) 407 – 9716
        Dial-in Quantity (Global): +1 (201) 493 – 6779
        Meeting ID: 13714992
        Webcast Obtain: http://community.viavid.com/index.php?id=143006

All listeners should ensure they are dialing in for the Interpace Biosciences meeting phone with the operator who will immediately put them into the contact. A webcast replay will be out there on the Company’s website ( www.interpace.com ) roughly two hours following completion of the contact and will be archived on the Company’s web-site for 90 times.

About Interpace Biosciences

Interpace Biosciences is an emerging chief in enabling personalised drugs, presenting specialized products and services alongside the therapeutic benefit chain from early analysis and prognostic planning to qualified therapeutic programs.

Clinical solutions, through Interpace Diagnostics, offers clinically useful molecular diagnostic assessments, bioinformatics and pathology solutions for analyzing chance of cancer by leveraging the most current technology in personalised medication for enhanced affected individual prognosis and management. Interpace has four commercialized molecular assessments and one particular test in a scientific analysis approach (CEP): PancraGEN® for the prognosis and prognosis of pancreatic most cancers from pancreatic cysts ThyGeNEXT® for the diagnosis of thyroid cancer from thyroid nodules using a future era sequencing assay ThyraMIR® for the diagnosis of thyroid most cancers from thyroid nodules utilizing a proprietary gene expression assay and RespriDX® that differentiates lung most cancers of key vs. metastatic origin. In addition, BarreGEN® for Barrett’s Esophagus, is at this time in a medical analysis application whereby we acquire information and facts from doctors employing BarreGEN® to support us in positioning the item for complete start, partnering and most likely supporting reimbursement with payers.

Pharma expert services, by means of Interpace Pharma Answers, offers pharmacogenomics screening, genotyping, biorepository and other personalized services to the pharmaceutical and biotech industries. Pharma providers also progress customized medicine by partnering with pharmaceutical, tutorial, and technology leaders to successfully integrate pharmacogenomics into their drug improvement and scientific demo plans with the goals of delivering safer, much more powerful medicines to sector additional quickly, and improving upon affected person treatment.

For far more facts, be sure to pay a visit to Interpace Biosciences’ web site at www.interpace.com.

Ahead-looking Statements

This push release consists of forward-searching statements within just the meaning of Segment 27A of the Securities Act of 1933, Part 21E of the Securities Trade Act of 1934 and the Non-public Securities Litigation Reform Act of 1995, relating to the Company’s future money and functioning efficiency. The Business has tried to identify ahead on the lookout statements by terminology which includes “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other phrases that convey uncertainty of future occasions or outcomes to discover these ahead-looking statements. These statements are primarily based on latest anticipations, assumptions and uncertainties involving judgments about, among other factors, long term financial, aggressive and market place problems and potential company conclusions, all of which are tough or difficult to forecast precisely and quite a few of which are further than the Company’s management. These statements also include regarded and mysterious threats, uncertainties and other variables that may possibly cause the Company’s actual outcomes to be materially different from these expressed or implied by any forward-wanting statements. On top of that, all ahead-on the lookout statements are subject to the “Risk Factors” in-depth from time to time in the Company’s most the latest Yearly Report on Sort 10-K filed on April 22, 2020, Existing Stories on Type 8-K and Quarterly Reviews on Form 10-Q. Due to the fact of these and other pitfalls, uncertainties and assumptions, undue reliance should not be positioned on these ahead-searching statements. In addition, these statements speak only as of the day of this push launch and, other than as may possibly be essential by regulation, the Organization undertakes no obligation to revise or update publicly any forward-seeking statements for any rationale.

Contacts:
Investor Relations
Edison Group
Joseph Eco-friendly/ Megan Paul
(646) 653-7030/7034
[email protected]/[email protected]